Mitigating the impact of the pandemic: a lens on kidney cancer and support groups
We are delighted to share with you a report titled [...]
Telaglenastat plus everolimus in advanced kidney cancer
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
Just over half of the patients from a phase 2 [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
Transforming lives, raising productivity
The Association of the British Pharmaceutical Industry (ABPI) has commissioned [...]
Tougher cancer diagnostic target as part of government’s ‘war on cancer’
The following was published in the Health Service Journal (HSJ) [...]
Breakthrough COVID-19 infections in vaccinated cancer patients
This study used real world data from the National COVID [...]
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
Treatment of local recurrence of kidney cancer after nephrectomy
Kidney cancer can come back after surgery to remove the [...]
Treatment of people who relapse on adjuvant pembrolizumab
Adjuvant treatment is treatment that is given after surgery to [...]
